Idelalisib

Generic Name
Idelalisib
Brand Names
Zydelig
Drug Type
Small Molecule
Chemical Formula
C22H18FN7O
CAS Number
870281-82-6
Unique Ingredient Identifier
YG57I8T5M0
Background

Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...

Indication

用于治疗:复发慢性淋巴细胞性白血病(CLL),与利妥昔单抗联用,在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。

Associated Conditions
Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath